Battling the two-headed dragon of prostate cancer targeted therapy.
Scott WilkinsonAdam G SowalskyPublished in: Molecular & cellular oncology (2020)
Neoadjuvant intense androgen deprivation therapy for high-risk localized prostate cancer is an emerging but unproven treatment paradigm that is hoped to delay or prevent disease recurrence. We found that a patient enrolled in a clinical trial harbored two completely independent prostate cancers that responded differently to this therapy.